{"id":"W2079627692","doi":"10.1158/0008-5472.sabcs-2136","title":"Safety of the anti-IGF-1R antibody CP-751,871 in combination with exemestane in patients with advanced breast cancer.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Exemestane; Medicine; Breast cancer; Tolerability; Internal medicine; Tamoxifen; Metastatic breast cancer; Oncology; Cancer; Estrogen receptor; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001031533,0.0009609244,0.00168326,0.0004531589,0.0002674701,0.0007161426,0.0006203981,0.0009588433,0.002671367],"category_scores_gemma":[0.0007820787,0.0004152097,0.0009586283,0.0003840826,0.0006624057,0.0006342832,0.0002765734,0.001805138,0.0006757881],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001000441,"about_ca_system_score_gemma":0.001510265,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001306739,"about_ca_topic_score_gemma":0.002570336,"domain_scores_codex":[0.9996297,0.0001650585,0.00002594725,0.0000543055,0.00004904138,0.00007584899],"domain_scores_gemma":[0.9994618,0.0001020096,0.0001362355,0.00002906192,0.00002389616,0.0002470143],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8465943,0.0163189,0.00427108,0.0009032263,0.000929429,0.0001609707,0.0001034945,0.001671741,0.02374723,0.000169289,0.001841575,0.1032887],"study_design_scores_gemma":[0.5127673,0.4618919,0.01710091,0.00006818699,0.0007495118,0.0002588567,0.00004045142,0.001216971,0.003620737,0.000121222,0.002132366,0.00003153132],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913903,0.00442623,0.0002436029,0.0003747477,0.0001020926,0.0009490757,0.0005852985,0.00006369615,0.001864844],"genre_scores_gemma":[0.9949131,0.001592007,0.0005043988,0.0004802556,0.0001591763,0.0006292253,0.0007876934,0.000009263544,0.0009248393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002671367,"threshold_uncertainty_score":0.008936584,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01669776976985819,"score_gpt":0.3387076439250603,"score_spread":0.322009874155202,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}